Indianapolis ranked fifth highest among the nation’s largest cities for the most positive reviews of physicians. On a five-point Patient Happiness Index, the average review by patients scored Indianapolis physicians at a 4.05. San Francisco physicians topped the list.
Indiana physicians and research organizations reaped more than $25 million in payments from 15 pharmaceutical firms in 2012, according to the most recent data made available by the not-for-profit group ProPublica. Lilly was the biggest spender and the IU medical school was the biggest recipient.
The economics of the Obamacare’s exchanges are proving attractive to both employers and workers, but a new poll shows that workers still don’t want to end up in them.
The areas around each of Indiana’s research university campuses—Bloomington, Indianapolis, Lafayette and South Bend—all boast outsize concentration of life sciences workers. Yet the state still lags on research, development and investment funding.
A new study found that common blood tests performed by hospital-owned facilities in the Indianapolis area were six to nine times more expensive than the same tests at independent lab facilities. Ouch!
Health care and health insurance were a mess long before Obamacare—and on a path to getting messier. That makes it awfully difficult to figure out how much blame and credit to give the law as it plays out in the marketplace. Here's my approach.
Since hospitals lose money on just about every patient except those with private insurance, they have been closing inner-city facilities and opening new facilities in the suburbs for the past four decades.
My post on a presentation by Community Health Network CEO Bryan Mills was interpreted in a stronger way than I intended. So let me set the record straight.
Shares of Endocyte Inc. skidded 15 percent Wednesday after industry giant Merck & Co. Inc. decided it would give up on developing Endocyte cancer drug vintafolide.
In a video presentation to his employees, Community Health CEO Bryan Mills discusses the threats hospitals face from retail clinics and employers—and how Community briefly discussed laying off 1,000 workers last year.
Medtronic Inc., the second-largest maker of medical devices, will be based in Ireland after the acquisition for tax advantages.
Whether the merger of the former rivals is good for Indianapolis will play out in the coming months. Huntingdon has 1,200 employees, most of them in the United Kingdom and Princeton, N.J. Harlan has about 2,300 employees worldwide, including 300 locally.
New data show eight out of 10 Hoosiers with private health insurance are covered by employer plans that are exempt from most Obamacare rules. So, rather than being an invasive train wreck, Obamacare may fail because it doesn’t affect enough people.
Dr. Ora Pescovitz is returning to Indianapolis after spending the past five years as CEO of the University of Michigan Health System.
Brose McVey is leading a new health care clinic company that is squarely aimed at helping individuals, the self-employed and even large businesses deal with the new health care reality that is emerging under Obamacare.
A San Diego venture capital firm has made a big bet on Indigo BioSystems Inc., which just installed its founder as the new chief executive.
While the biggest hospital profit margins are made in the suburbs, the biggest pile of cash—$353 million in 2012—is made at the three downtown campuses run by Indiana University Health. In fact, those hospitals generated 32 percent of all operating gains posted by central Indiana hospitals in 2012.
Two new studies show that Americans have every economic incentive to consume too much food and then, when that overeating creates health problems for them, to consume lots of health care to fix it.
Indiana ranks 10th in the nation for the highest spending on health care and 10th in the nation for the number of adults missing six or more teeth. That’s not a coincidence. Hoosiers do a poor job of taking care of themselves, and we end up paying for it in higher taxes and health insurance premiums.
Radiopharmaceuticals maker Zevacor Molecular plans to open a $40 million isotope-production facility in Noblesville, creating nearly 50 good-paying jobs within five years.
